Oz-UK

OzUK Laboratories is a specialized CRO and service provider positioned as a leader in pressurized metered dose inhaler (pMDI) product development. Founded in 2015, the company capitalizes on over three decades of team expertise to guide pharmaceutical clients through complex challenges, most notably the industry-wide transition from high-GWP propellants to low-GWP alternatives. Its core offering, the MDISprint™ platform, employs a concurrent, lean methodology to expedite time-to-market for both innovator and generic inhalation products. OzUK operates through strategic partnerships with component suppliers and CDMOs, offering a comprehensive, asset-light service model.

MDISprint™ - A lean, concurrent development methodology for pMDI products that integrates formulation design, CMC, component selection, and partner management to accelerate time-to-market. Supported by specialized pilot-scale filling capabilities for low-GWP propellants.

OzUK competes with specialized inhalation CROs (e.g., Kindeva Drug Delivery's service arm, formerly 3M) and the inhalation service divisions of large CDMOs (e.g., Lonza, Recipharm). Its differentiation lies in its exclusive focus on pMDIs, deep historical transition expertise, and the proprietary, speed-oriented MDISprint™ process.